Mentari Therapeutics, Inc. (MTRI)
Industry: Biotechnology
Mentari Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 17, 2026 | 19.27 | 20.00 | 16.93 | 17.50 | 171,052 |
| Nov 16, 2026 | 17.72 | 19.87 | 17.72 | 19.87 | 11,681 |
| Nov 13, 2026 | 19.02 | 20.00 | 18.40 | 18.60 | 11,958 |
| Nov 12, 2026 | 15.75 | 19.17 | 14.76 | 18.35 | 145,626 |
| Nov 11, 2026 | 12.50 | 16.50 | 12.50 | 15.61 | 60,107 |
| Nov 10, 2026 | 14.35 | 15.84 | 12.20 | 12.20 | 57,481 |
| Nov 9, 2026 | 14.80 | 16.95 | 12.34 | 16.00 | 54,288 |
| Nov 6, 2026 | 13.71 | 16.44 | 13.70 | 15.56 | 27,155 |
| Nov 5, 2026 | 14.00 | 15.49 | 12.88 | 13.21 | 32,864 |
| Nov 4, 2026 | 18.00 | 18.30 | 16.20 | 17.50 | 12,062 |
| Nov 3, 2026 | 15.30 | 17.70 | 15.10 | 16.80 | 17,483 |
| Nov 2, 2026 | 15.95 | 16.50 | 14.85 | 16.30 | 14,055 |
| Oct 30, 2026 | 15.50 | 16.10 | 15.10 | 16.00 | 3,668 |
| Oct 29, 2026 | 15.90 | 16.40 | 15.90 | 16.25 | 3,740 |
| Oct 28, 2026 | 16.30 | 16.70 | 15.90 | 15.99 | 4,321 |
| Oct 27, 2026 | 15.90 | 16.80 | 15.40 | 15.90 | 11,478 |
| Oct 26, 2026 | 14.40 | 16.21 | 14.10 | 15.90 | 29,439 |
| Oct 23, 2026 | 13.21 | 15.40 | 13.20 | 14.40 | 12,592 |
| Oct 22, 2026 | 13.60 | 13.75 | 13.30 | 13.30 | 829 |
| Oct 21, 2026 | 13.20 | 13.90 | 13.20 | 13.60 | 2,719 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Director | Grant/Award | 37.0K | -- | Nov 9, 2026 | |
| Director | Grant/Award | 37.0K | -- | Nov 9, 2026 | |
| See Remarks | Grant/Award | 1.56M | -- | Nov 9, 2026 | |
| See Remarks | Grant/Award | 171.0K | -- | Nov 9, 2026 | |
| Director | Grant/Award | 37.0K | -- | Nov 9, 2026 | |
| See Remarks | Grant/Award | 257.0K | -- | Nov 9, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Fairmount Funds Management LLC · joint filing· may incl. warrants· filed Nov 2026 | 10.6M | 20.0% | 13D |
Commodore Capital LP · joint filing· may incl. warrants· filed Nov 2026 | 3.0M | 5.6% | 13G |
Deep Track Capital, LP · joint filing· may incl. warrants· filed Nov 2026 | 3.0M | 5.6% | 13G |
EVENTIDE ASSET MANAGEMENT, LLC | 435.4K | -- | 13F |
Seven Fleet Capital Management LP | 107.0K | -- | 13F |
ADAR1 Capital Management, LLC · filed Oct 2026 | 94.4K | 17.2% | 13G |
Vivo Capital, LLC | 82.5K | -- | 13F |
Bruno Julianne Director | 33.4K | -- | FORM 4 |
SABBY MANAGEMENT, LLC · filed Jan 2026 | 28.0K | 9.9% | 13G |
Pernice Michelle Patricia Director | 27.9K | -- | FORM 4 |
Insiders
- Pernice Michelle PatriciaDirector
- Bruno JulianneDirector
- Divis Gregory JSee Remarks
- Hagen Brett RSee Remarks
- Sandler Laura LeeDirector
- Seurer Jerad G.See Remarks
- Shegog ToddDirector
- ADAR1 Capital Management, LLC10% Owner
- Vivo Opportunity, LLC10% Owner
- Lemerond NicoleDirector
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids.
Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief.
Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research.
It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently.
The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada.
It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.
based on 52.81M shares outstanding
30d Avg
32.78K
60d Avg
18.58K
90d Avg
15.03K
Signal8's dilution snapshot of MTRI as of Sep 30, 2026 records an effective S-3 shelf registration (effective Mar 30, 2026), an at-the-market sales agreement dated Apr 7, 2022 and 3 outstanding warrant series, from SEC filings. 1 insider reported 16 open-market purchases of MTRI stock on Form 4 in the 90 days to Nov 18, 2026. Mentari Therapeutics, Inc. (NASDAQ: MTRI) traded at $17.50 on Nov 17, 2026, down 11.93% from the previous close of $19.87. 52-week range: $5.75 to $23.30. The company is in the Healthcare sector (Drug Manufacturers - Specialty & Generic).